Robert Orlowski, Deputy Chair of Lymphoma/Myeloma, Vice Chair of MM Research, and Florence Maude Thomas Cancer Research Professor at the University of Texas MD Anderson Cancer Center, shared a post on X:
“Myeloma Paper of the Day:
Phase I/II of twice-weekly ixazomib + pom/dex in RRMM finds ORR 60.0%, 24.0% ≥VGPR (28.9% ≥VGPR in 38 pts who got RP2D); median DOR was 18.0 and 19.3 mos, PFS was 13.9 & 17.8 mos, and 3-year OS rates 85.2% and 80.3%.”
Title: A phase I/II study of twice-weekly ixazomib plus pomalidomide and dexamethasone in relapsed and refractory multiple myeloma
Authors: Omar Nadeem, Robert A. Redd, Peter M. Barth, Trevor J. Bayliss, Jacob P. Laubach, Giada Bianchi, Clifton C. Mo, John L. Reagan, Shonali Midha, Adam S. Sperling, Yuxin Liu, Monique A. Hartley-Brown, Madison P. Chuma, Taylor Nicholson, Emily J. Benjamin, Alexandra Distaso, Eileen Regan, Ann Marie Van Hof, Adam J. Dahill, Rachel Goldbaum, Keemia Mohammadi, Audrey Lewis, Raja Poda, Nikhil C. Munshi, Kenneth C. Anderson, Irene M. Ghobrial, Paul G. Richardson
You can read the Full Article in Haematologica.
You can find other articles featuring Robert Orlowski on OncoDaily.
